Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

193.72 +0.50 (+0.26%)
Official Closing Price Updated: 7:00 PM EDT, Oct 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
The Magnificent 7 Boom Just Triggered A Dot-Com Era Warning
The Magnificent Seven tech giants are now worth $21 trillion—8x more than top health care stocks, echoing dot-com bubble extremes. 
Via Benzinga
Jabil Set For Major AI Growth As Other Segments Falter: Analyst
Jabil Inc. to report fiscal Q4 earnings; AI and cloud revenue key factors for outlook. Analyst expects conservative guidance. 
Via Benzinga
Topics Artificial Intelligence
Evolving Investment Strategies for an Uncertain Market
In an era marked by persistent inflation, fluctuating interest rates, geopolitical tensions, and rapid technological shifts, investors are facing an increasingly complex and unpredictable financial... 
Via MarketMinute
Topics Bonds ETFs Economy
Kenvue Stock Hits Record Low As Trump Urges Pregnant Women To ‘Fight Like Hell’ Against Tylenol: Retail Stays Bullish
Via Stocktwits
Topics Government
This Johnson & Johnson Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
 
Via Benzinga
Johnson & Johnson Ends Overseas Sales Of Acid Reflux Device Citing Market Factors
Johnson & Johnson will halt international sales of its Linx reflux device, sparking concern among surgeons over limited options for GERD patients. 
Via Benzinga
Beyond The Numbers: 10 Analysts Discuss Johnson & Johnson Stock
 
Via Benzinga
The Ultimate Dividend King Drug Stock to Buy With $1,000 Right Now
This out-of-favor industry could be in the doghouse for years. Do you buy for yield or for dividend safety? 
Via The Motley Fool
Jim Cramer Says Trump Is Creating 'A Nightmare' For Kenvue As President Links Tylenol With Autism
Jim Cramer says Trump creates a "nightmare" for Kenvue after linking Tylenol to autism. Learn why KVUE stock is plunging amid lawsuit fears. 
Via Benzinga
Topics Government Lawsuit
Johnson & Johnson Stock Weathers Trump’s Tylenol Attacks Better Than Kenvue Amid Dipping Retail Confidence — What’s Holding Losses in Check?
Guggenheim’s upgrade and new data on J&J’s experimental depression drug helped steady sentiment, even as investors weighed political scrutiny and ongoing litigation risks. 
Via Stocktwits
Topics Government
U.S. Government Shutdown Looms: A Guide for Investors Navigating Political and Economic Uncertainty
As the perennial specter of a U.S. government shutdown once again casts a shadow over Washington, D.C., financial markets are bracing for potential turbulence. The failure of Congress to agree on... 
Via MarketMinute
Topics Bonds Economy
Kenvue Stock Sinks To Record Low As Trump To Reportedly Link Tylenol Use To Autism
The latest controversy poses a new reputational challenge for Kenvue, which was spun out of Johnson & Johnson in 2023. 
Via Talk Markets
Topics Government
The Enduring Appeal of Dividend Aristocrats: A Beacon of Stability in Turbulent Markets
In an era marked by fluctuating interest rates, geopolitical uncertainties, and shifting economic landscapes, a select group of companies known as "Dividend Aristocrats" continues to shine as pillars... 
Via MarketMinute
Topics ETFs Economy Energy
The Unyielding Power of Dividends: A Blueprint for Enduring Wealth
In an era of fluctuating financial markets and evolving economic landscapes, the allure of dividend-paying stocks as a cornerstone for building long-term wealth remains as potent as ever. As investors... 
Via MarketMinute
Topics Retirement Supply Chain
Growth Titans: Eli Lilly's Weight-Loss Surge vs. Johnson & Johnson's Diversified Might
The pharmaceutical landscape is currently a tale of two giants employing vastly different, yet highly successful, growth strategies. Eli Lilly and Company (NYSE: LLY) has placed an extraordinary bet on... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Johnson & Johnson's Uninterrupted Dividend Growth: Innovation in Medicine and MedTech Drives Strong Q2 2025 Performance
Johnson & Johnson (NYSE: JNJ), the global healthcare titan, has once again underscored its formidable market position and unwavering commitment to shareholder value, reporting a robust second quarter... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
Kenvue, J&J Retail Traders Cautious As US Health Officials Reportedly Plan To Announce Tylenol Links To Autism
Tylenol is one of the most common medicines for reducing pain and fever, and a major product for Kenvue. 
Via Stocktwits
Topics Government
Could These 3 Dividend Kings Be Worth $1 Trillion in 10 Years?
The trillion-dollar club will probably need to make room for at least one Dividend King in the coming years. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
Ben & Jerry's Co-Founder Resigns In Protest As Politics Continue To Influence Corporate Exits
Jerry Greenfield, of Ben & Jerry's fame, didn't resign over personal controversy—he quit because his company stopped being political enough. 
Via Benzinga
What Is Considered a Good Stock Dividend? 3 Healthcare Stocks That Fit the Bill
A high yield is only one part of the story when it comes to picking dividend stocks. 
Via The Motley Fool
Topics Intellectual Property
Johnson & Johnson Confronts the End of its Talc Legacy with Multi-Billion Dollar Settlements
Johnson & Johnson (NYSE: JNJ) is navigating a critical juncture in its protracted legal battle over talc-based baby powder. The healthcare behemoth has announced a tentative $700 million settlement... 
Via MarketMinute
Topics Bankruptcy Death Lawsuit
P&G's Q3 2025: Sales Miss Overshadows Earnings Beat Amidst Global Headwinds
Procter & Gamble (NYSE: PG) recently disclosed its fiscal third-quarter 2025 results, presenting a nuanced financial picture that has stirred investor sentiment. While the consumer goods titan managed... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
Johnson & Johnson Unleashes Triple Threat: Bladder Cancer Breakthrough, Psoriasis Game-Changer, and Myasthenia Gravis Milestone Signal New Pharma Era
Johnson & Johnson (NYSE: JNJ) is making significant waves in the pharmaceutical landscape, announcing a trio of pivotal developments that underscore its robust pipeline and strategic focus on unmet... 
Via MarketMinute
Lilly's $5 Billion Virginia Investment: A Game Changer for GLP-1 and Oncology Drug Production
Eli Lilly and Company (NYSE: LLY) has announced a colossal $5 billion investment to establish a new, state-of-the-art manufacturing facility in Goochland County, Virginia. This significant expansion, a... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes
Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca... 
Via MarketMinute
Johnson & Johnson's Tecvayli-Darzalex Combo Shows 100% Response In Newly Diagnosed Myeloma Patients
Johnson & Johnson's Tecvayli-Darzalex regimen showed 100% response rates and high MRD negativity in newly diagnosed multiple myeloma patients. 
Via Benzinga
Can Regeneron Change The Paradigm In Multiple Myeloma — And Undercut J&J?
The company is looking to take on Johnson & Johnson in treating patients with a precursor to multiple myeloma. 
Via Investor's Business Daily
Recent Report Shows That Rep. Thomas Kean Bought Up to $45K Worth of Amcor Stock
 
Via Benzinga
8 Dividend Growth Stocks Every Investor Should Consider
These dividend powerhouses compound wealth through decades of consecutive increases and sustainable payout ratios. 
Via The Motley Fool
Topics Artificial Intelligence Economy
Melanoma Data Study Boosts J&J Partner Nanobiotix Stock On Thursday
Nanobiotix reported melanoma study data showing JNJ-1900 delivered 47.4% response rate, 78.9% disease control, and 14.6 months survival. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.